Clinical Decision-Making for Drug-Resistant Tuberculosis

Raison d'être

Drug-resistant tuberculosis (DR-TB) is an important challenge for clinicians. With the introduction of molecular diagnostic tests, such as the Xpert MTB/RIF assay and Line Probe Assays, the notification of DR-TB is increasing and the time to diagnosis can be shortened, allowing earlier treatment initiation. Shorter treatment regimens (STR) have been recommended by WHO since 2016, thus simplifying treatment for patients and National TB Programs alike. Access to bedaquiline, delamanid, linezolid, and clofazimine is increasing and guidelines are adapted frequently. Clinicians require training in the use of these new diagnostic tools, the interpretation of guidelines, and in making informed choices for treatment initiation and monitoring and in adequate and timely clinical decision making.

For this course, we have a partnership with: Damien Foundation, MSF, University Hospital Leuven, Nottingham Trent University and PATH Ukraine.

This blended course offers interdisciplinary and interactive training on clinical aspects of DR TB diagnosis and care. It consists of an 11-week online training (includes a break of 3 weeks) followed by 2 weeks face-to-face (includes 1 public holiday).

Student Investment Time during the online part: 10 hours per week = 80 hours.

Student Investment Time during the face-to-face part: 7,5 hours per day = 67,5 hours.

IMPORTANT: The course is offered in a "hybrid" way. This means that participants can follow the face-to-face part online, in case they cannot travel.